Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Long-term side effects of neurotoxicity of antitumor therapy in children who survived lymphoid tumors
https://doi.org/10.33667/2078-5631-2024-32-50-54
Abstract
Relevance. Improving the diagnosis and treatment of children with lymphoid tumors (LT) contributes to an increase in the number of cured patients. Antitumor therapy has a side effect on the nervous system, and can lead to neurotoxic consequences. Due to the increased life expectancy of children cured of LT, the assessment of the long-term neurotoxic effects of antitumor therapy is relevant.
Objective: based on the literature data, to study the long-term neurotoxic side effects of antitumor therapy in children cured of LT.
Material and methods. When writing a literature review, data were analyzed in specialized medical databases Pubmed, Scopus, Web of Science on research in children cured of lymphoid tumors from 1993 to 2023.
Results. In cured children from lymphoid tumors, the long-term neurotoxic effects of therapy containing methotrexate in high doses are manifested by neurocognitive decline and structural changes in the brain. Late peripheral neuropathy caused by vincristine affects the quality of life of patients in physical and social aspects. However, the prognostic parameters of long-term neurotoxic effects in children cured of LT have not been determined. The issues of monitoring patients in the long term have not been sufficiently studied. This will contribute to the rehabilitation and long-term follow-up of patients with oncohematological diseases, and improve their quality of life.
About the Author
E. I. Kuznetsova
N.N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Kuznetsova Elena I., Dr Bio Sci, senior researcher at Functional Diagnostics Dept.
Moscow
References
1. Valiev T.T. Modern strategy of diagnostics and treatment of non-Hodgkin’s lymphomas in children. Abstract of the dissertation for the degree of Doctor of Medical Sciences / Rus. oncol. research center named after N.N. Blokhin, Russian Academy of Medical Sciences. Moscow, 2014. (In Russ.).
2. Valiev T.T., Morozova O.V., Kovrigina A.M., Makhonova L.A., Sholokhova E.N., Serebryakova I.N., Popa A.V., Tupitsyn N.N., Mentkevich G.L. Diagnostics and treatment of anaplastic large cell lymphomas in children. Hematology and transfusiology. 2012. Vol. 57. No. 1. P. 3–9. (In Russ.).
3. Belyaeva E.S., Susuleva N.A., Valiev T.T. The Importance of Intensive Chemotherapy for the Treatment of Children with Advanced Hodgkin Lymphoma. RMJ. Mother and Child. 2020. Vol. 3. No. 2. P. 149–153. (In Russ.).
4. Vinogradova Yu.E., Lutsenko I.N., Kaplanskaya I.B., Vorobyov I.A., Samoilova R.S., Gorgidze L.A., Ryzhikova N.A., Valiev T.T., Gilyazitdinova E.A., Dzhulakyan U.L., Egorova E.K., Zvonkov E.E., Krasilnikova B. B., Magomedova A. U., Margolin O. V., Maryin D. S., Kremenetskaya A. M., Kravchenko S.K., Vorobyov A.I. Efficiency of Therapy for Various Variants of Anaplastic Large T-Cell Lymphomas. Therapeutic archive. 2008. Vol. 80. No. 7. P. 33–37. (In Russ.).
5. Baryakh E.A., Kremenetskaya A.M., Kravchenko S.K. et al. New short high-intensity protocol for the treatment of adult Burkitt-like lymphoma BPL–M-04: intermediate results. Hematology and transfusiology. 2006. Vol. 51. No. 6. P. 3–11. (In Russ.).
6. Śliwa-Tytko P., Kaczmarska A., Lejman M., Zawitkowska Neurotoxicity J. Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy Int J Mol Sci. 2022 15;23(10):5515. doi: 10.3390/ijms23105515
7. Campbell J M, Bateman E, Stephenson M D, Bowen J M, Keefe D M, Peters M D J Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses Cancer Chemother Pharmacol 2016 Jul;78(1):27–39. doi: 10.1007/s00280-016-3043-5.
8. Cheung YT, Sabin ND, Reddick WE, Bhojwani D, et al. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. The Lancet Haematology. 2016;3(10): e456–e466. doi: 10.1016/s2352–3026 (16) 30110-7.
9. Wen J, Maxwell RR, Wolf AJ, Spira M, et al.. Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model. Neuropharmacology. 2018;139:76–84. doi: 10.1016/j.neuropharm.2018.07.007
10. Guryeva O.D., Savelyeva M.I., Valiev T.T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Russian Journal of Pediatric Hematology and Oncology. 2021. Vol. 8. No. 4. P. 60–70. (In Russ.).
11. Taylor OA., Hockenberry MJ, McCarthy K., et., al. Evaluation of Biomarkers of Oxidative Stress and Apoptosis in Patients With Severe Methotrexate Neurotoxicity: A Case Series. J Pediatr Oncol Nurs. 2015 Sep-Oct;32(5):320–5. doi: 10.1177/1043454214563409.
12. Childrens Oncology Group Long Term Follow-Up guidelines Version 5.0. 2018
13. Daetwyler E, Bargetzi M, Otth M, et.al. Late effects of high-dose methotrexate treatment in childhood cancer survivors – a systematic review BMC Cancer. 2022; 22: 267. Published online 2022 Mar 14. doi: 10.1186/s12885-021-09145-0
14. Kadan-Lottick N S, Zeltzer LK, Liu Qi, et.al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. Natl Cancer Inst. 2010;102(12):881–93. doi: 10.1093/jnci/djq156.
15. Lofstad GE, Reinfjell T, Hestad K, et.al. Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. Acta Paediatr. 2009 Jan;98(1):180–6. doi: 10.1111/j.1651–2227.2008.01055.x.
16. Mennes M, Stiers P, Vandenbussche E, et. al. Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Pediatr Blood Cancer. 2005;44(5):478–86. doi: 10.1002/pbc.20147. PMID: 15918215
17. Jansen N C, Kingma A, Schuitema A, Post-treatment intellectual functioning in children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only: a prospective, sibling-controlled study Eur J Cancer. 2006;42(16):2765–72. doi: 10.1016/j.ejca.2006.06.014 PMID: 16935489.
18. Tabone MD, Leverger G. Outcome of children cured of acute lymphoblastic leukemia Bull Acad Natl Med. 2009;193(7):1519–28.
19. Kuznetsova E.I., Gorbachevskaya N.L. Bioelectrical activity of the brain and the functional state of the brain vessels in adolescents with long-term remission (5–12 years) cured of lymphoid tumors. Oncopediatrics. 2017, Vol. 4, No. 2, pp. 115–122. (In Russ.). DOI: 10.15690/onco.v4i2.1705
20. Zając-Spychała O, Pawlak M, Karmelita-Katulska K et.al. Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate. Leuk Lymphoma 2018;59(10):2342–2351. doi: 10.1080/10428194.2018.1434879.
21. Kesler SR, Wilburn RO, Reddick E, et al. Brain Network Connectivity and Executive Function in LongTerm Survivors of Childhood Acute Lymphoblastic Leukemia. Brain Connect.2018;8(6):333–342. doi: 10.1089/brain.2017.057430
22. Elens I, Deprez S, Danckaerts M, et.al., Neurocognitive Sequelae in Adult Childhood Leukemia Survivors Related to Levels of Phosphorylated Tau J Natl Cancer Inst. 2017;109(7). doi: 10.1093/jnci/djw321.
23. Khan RB, Morris EB, Pui CH, et.al., Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies J Child Neurol. 2014;29(6):774–81. doi: 10.1177/0883073813488675
24. Triarico S., Romano A., Attinà G., et.al., Vincristine-Induced Peripheral Neuropathy (VIPN) in Pediatric Tumors: Mechanisms, Risk Factors, Strategies of Prevention and Treatment. Int J Mol Sci.2021;22(8):4112. doi: 10.3390/ijms22084112.
25. Feras MH, Farqad J., Hamdan B, et.al. Vincristine-induced neuropathy in rat: electrophysiological and histological study. Exp Brain Res 2006; 173(2):334–45. doi: 10.1007/s00221-006-0499-2
26. Lavoie Smith EM, Li L, Chiang C, Thomas K, et al. Patterns and Severity of Vincristine-Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. J Peripher Nerv. Syst (2015) 20:37–46. doi: 10.1111/jns.12114 – DOI – PMC – PubMed
27. Ramchandren S., Leonard M., Mody R.J., et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J. Peripher. Nerv. Syst. 2009.Vol.14, № 3.P.184–189.
28. Tay Ch. G., Lee V.W. M., Ong L. Ch., et.al. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2017 64(8). doi: 10.1002/pbc.26471. PMID: 28139029
29. Kroczka S, Stepien K, Witek-Motyl I, Klekawka T, Kapusta E, Biedron A, et al.. Polyneuropathy in Acute Lymphoblastic Leukemia Long-Term Survivors: Clinical and Electrophysiological Characteristics With the Impact of Radiotherapy. Front Pediatr (2021) 8:526235. doi: 10.3389/fped.2020.526235
30. Postma T J Benard B A Huijgens P C. Long-term effects of vincristine on the peripheral nervous system J Neurooncol 1993 15(1):23–7. doi: 10.1007/BF01050259 PMID: 8384253
31. Diouf B., Evans W.E. Pharmacogenomics of Vincristine-induced peripheral neuropathy: Progress continues. Clin.Pharmacol. Ther. 2019;105:315–317. doi: 10.1002/cpt.1209.
32. Joshi J, Tanner L, Gilchrist L, Bostrom B. Switching to Bortezomib may Improve Recovery From Severe Vincristine Neuropathy in Pediatric Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2019. 41:457–62. doi: 10.1097/MPH.0000000000001529
33. Azoulay D., Giryes S., Nasser R. et al. Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism J Clin Neurol. 2019;15(4):511–516. https://doi.org/10.3988/jcn.2019.15.4.511
Review
For citations:
Kuznetsova E.I. Long-term side effects of neurotoxicity of antitumor therapy in children who survived lymphoid tumors. Medical alphabet. 2024;(32):50-54. (In Russ.) https://doi.org/10.33667/2078-5631-2024-32-50-54
Views:
152
Email this article 